article thumbnail

How Pharmacogenomics may finally realise its promise

pharmaphorum

The program is orchestrated by Coriell Life Sciences, and nearly half of the 5,000 enrolled members have already made immediate shifts to their medication regimen which are showing positive results, both from an individual impact as well as a cost-savings perspective.

Genome 85
article thumbnail

LabCorp Backs Resolution Bioscience’s Liquid Biopsy Test for NSCLC

XTalks

The leading global life science company is set to introduce Resolution Bio’s ctDx Lung assay , a non-invasive liquid biopsy test for patients with non-small cell lung cancer (NSCLC). LabCorp (NYSE:LH) may help lead the way with its backing of Resolution Bioscience’s new diagnostic blood test for lung cancer.

Gene 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Supercharging AI-drug discovery with strategic multiomic biobanks 

Drug Discovery World

Narain , PhD, President and CEO of BPGbio asks how a better calibre of biobanks in life sciences can lead to more drugs making it to market.

article thumbnail

Why Proviral DNA Drug Resistance Testing is Useful in Guiding Treatment Decisions for HIV-1 Patients

XTalks

Proviral DNA Genotyping. In the HIV space, proviral DNA resistance testing is the newest genotypic resistance testing to be incorporated into the day-to-day management of patients living with HIV, explains Dr. Walworth. Importantly, ARV treatment does not affect the proviral DNA genome that persists in latently infected cells.

DNA 98
article thumbnail

New Study Suggests Pregnant Women Should Avoid Caffeine Altogether. Here’s Why

XTalks

The results did not differ based on fast or slow caffeine metabolism genotype. Increasing caffeine amounts were significantly associated with lower birth weight, shorter length and smaller head, arm, and thigh circumference.

article thumbnail

How MedFluid is Targeting Antimicrobial Resistance with its Personalized Infection Screening Tool

XTalks

It identifies bacteria using both genotypic and phenotypic assessments within 1.5 The tool can select different combinations of multiple antibiotics deemed suitable for treating specific bacterial infections. MedFluid’s personalized antibiotic screening platform—called fAST—is a fully automated tool that is based on microfluidics technology.

article thumbnail

BridgeBio Pharma’s Nulibry Approved as First Treatment for Molybdenum Cofactor Deficiency Type A

XTalks

In the analysis involving 31 patients, 13 were treated with Nulibry and compared to 18 genotype-matched untreated patients from the history control group. The efficacy of Nulibry in the treatment of MoCD Type A was demonstrated in data from three different clinical trials that was compared to data from a natural history study.